Sponsor vs SME-Led UAT in Clinical Trials

User Acceptance Testing (UAT) in clinical trials is a critical step in validating that systems such as IRT, eCOA, and other eClinical platforms are fit for real-world study execution. As trial complexity increases and timelines compress, sponsors are rethinking how UAT is structured, shifting from fully sponsor-led execution toward more flexible, hybrid, and SME-supported models.

For most sponsors, the question is no longer whether UAT is required; the question is how to execute an effective, scalable clinical trial UAT strategy.

Four Common UAT Execution Models in Clinical Trials

Most UAT approaches fall into one of four models: 

1. Sponsor-Led UAT—In a sponsor-led UAT, the sponsor owns and executes all UAT activities internally. This works well with established teams with prior experience, with lower-complexity clinical trials, or when internal bandwith is sufficient.

Where it breaks down: 

• Competing priorities and limited resourcing 
• New system implementations or complex configurations 
• Inconsistent testing depth across studies 

2. Vendor-Supported UAT —In a vendor-supported UAT, the system vendor or CRO provides support during UAT execution, often focused on system configuration. This works well with for basic of functional validation and configuration walkthroughs.

Where it breaks down: 

• Testing may follow system configuration rather than challenge it 
• Limited independence in validation 
• Gaps in real-world, study-specific scenarios 
  

3. SME-Led UAT (Independent Support) —Specialized subject matter experts (SMEs) support UAT execution, script development, or both. It works well with complex IRT UAT or eCOA UAT scenarios, with studies that require deep clinical supply or operational expertise, or with accelerated timelines where efficiency is critical.

Where it requires structure: 

• Clear alignment on ownership and sign-off 
• Integration with sponsor processes and documentation 

4. Hybrid UAT (Sponsor-Owned, SME-Enabled) —In this model, the sponsor retains ownership of UAT while leveraging SMEs for targeted support.  This model works best in scenarios where sponsors must balance accoutability with limited internal capacity, along with programs that require both speed and depth of validation.

UAT in Clinical Trials: Execution vs. Ownership 

One of the most common misconceptions in clinical trial UAT is that outsourcing execution means outsourcing responsibility. In reality, regulatory expectations remain clear: The sponsor is ultimately responsible for confirming that the system is fit for its intended use. 

What is evolving is not ownership, but execution.  Sponsors are increasingly separating accountability (which remains internal) and execution support (which can be strategically externalized). This shift enables organizations to maintain control while improving consistency, coverage, and speed across UAT for clinical trial systems. 

Why the Traditional Sponsor-Led UAT Model Is Under Pressure 

Several industry trends are making fully sponsor-led UAT more difficult to sustain: 

• Reduced internal system expertise due to leaner teams 
• Increasing configuration complexity across IRT, eCOA, and eClinical platforms 
• Compressed study startup timelines 
• Greater regulatory emphasis on risk-based UAT and traceability 

These pressures do not eliminate the need for sponsor involvement, but they do make a purely internal model harder to execute consistently. 

Where SME-Led UAT Support Adds the Most Value 

SME-led UAT delivers tremendous benefits based on the experience experts bring to the UAT process across systems. The strongest clinical trial UAT strategies use SMEs to: 

• Structure testing around real study workflows 
• Identify gaps early during requirements and design review 
• Support complex or high-risk execution 
• Enable faster, more focused UAT cycles 

This is especially important in areas such as site and patient workflows, drug supply and inventory, and edge-case and exception handling scenarios. These are often the areas where risk is least visible, but most impactful at study go-live.

How to Choose the Right Clinical Trial UAT Model 

There is no single “correct” UAT execution model, but there is a right fit based on study needs.

A simple framework to consider:

• Lower complexity + experienced internal team → Sponsor-led UAT may be sufficient
• Moderate complexity + limited bandwidth → Hybrid UAT model is often optimal
• High complexity or accelerated timelines → SME-enabled UAT becomes critical

The goal is not to replace sponsor ownership, but to bring in the right SME expertise, with the sponsor maintaining oversight and engagement even when not directly responsible for every deliverable.

The Larger Shift in Clinical Trial UAT Strategy 

As clinical trial UAT becomes more complex across IRT, eCOA, and eClinical systems, execution models are evolving beyond traditional approaches. Sponsors are moving toward risk-based UAT strategies with a greater alignment between testing and real-world execution along with more flexible models that balance internal ownership with external expertise.

This shift reflects a broader change in how clinical trial technology is validated: from documenting system functionality to ensuring confidence in study execution. 

A Final Thought on eClinical System UAT 

UAT in clinical trials has always been more than a technical requirement, it is the final checkpoint before real patients, real sites, and real supply chains depend on the system. As execution models evolve, the most effective sponsors are not asking whether to involve external support, but how to do so strategically. Because ultimately, the success of UAT is not defined by who executes it—it is defined by how well the system performs when it matters most. 

With CSC’s expert-led approach, every test is an opportunity to improve your UAT and eClinical system launch. Learn more about CSC’s UAT Services today.